Abstract 1084
Background
Immune checkpoint inhibitors (ICI) have been demonstrated to improve overall survival (OS) in several cancer types. Atypical patterns of response have been reported including durable responses, pseudoprogression and hyperprogression. We evaluated the occurrence of dissociated response (DR) on immunotherapy.
Methods
We retrieved all patients treated at the Curie Institute with an ICI either alone or in combination with another ICI in the frame of a clinical trial. Patients had to have a baseline CT-scan and at least one follow-up CT-scan, and at least two target lesions (TLs). There was no selection on tumor type. All TLs on CT-scans were assessed by two independent readers according to RECIST 1.1. Three types of DR were evaluated: 1) one TL in partial or complete response (CR/PR) and one progressive TL (DR1), 2) one stable TL and one progressive TL (DR2), and 3) one TL in CR/PR and one stable TL (DR3). Finally, we evaluated the impact of previous radiotherapy and biopsy on TLs on the occurrence of DRs.
Results
1,246 measures of 272 TLs were performed in the 100 patients who met our inclusion criteria. The median number of TLs per patient was 3 [range: 2-5]. 49 out of the 272 TLs (18%) had received prior radiotherapy, and 38 (14%) had been biopsied. Median progression-free survival (PFS) was 3.8 months. Median OS was 13.4 months. Best overall response per patient was a PR/CR in 22%, stable disease (SD) in 33% and progressive disease (PD) in 45%. Best overall response on 272 TLs was a PR/CR in 52 TLs (19%), SD in 142 TLs (52%) and PD in 78 TLs (29%). DR1 were observed in 8% of patients, whereas DR2 and DR3 were observed in 44% and 10% of patients, respectively. While prior irradiation on TLs did not correlate with the occurrence of DRs, DRs were more common when one TL was biopsied ORa = 2.22 (1.28, 3.86) (p = 0.004).
Conclusions
DR with a responding TL and a progressive TL according to RECIST1.1 was observed in 8% of patients. While prior irradiation on TLs did not correlate with the occurrence of DRs, DRs were more common when one TL was biopsied.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Loirat: Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Novartis; Honoraria (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Pfizer. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck; Advisory / Consultancy: Serono; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Nanobiotix; Advisory / Consultancy: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract